دواعي استعمال ثرمبوريست 90مجم 7 اقراص

Ticagrelor 90 mg film-coated tablets (oral reversible P2Y12 platelet inhibitor), Egyptian generic.

• Reduce the risk of cardiovascular death, myocardial infarction and stroke in acute coronary syndrome or history of MI (also reduces stent thrombosis in patients stented for ACS).الفئة: AdultsDailyMed (U.S. National Library of Medicine)
• Reduce the risk of a first MI or stroke in coronary artery disease at high risk for such events.الفئة: AdultsDailyMed (U.S. National Library of Medicine)
• Reduce the risk of stroke in acute ischaemic stroke (NIHSS <=5) or high-risk TIA.الفئة: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>5%): bleeding and dyspnoea.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• History of intracranial haemorrhage.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Active pathological bleeding (e.g. peptic ulcer, intracranial haemorrhage).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity (e.g. angioedema) to ticagrelor or any component.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Boxed warning: can cause significant, sometimes fatal bleeding; do not start in patients undergoing urgent CABG; if possible manage bleeding without stopping.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Premature discontinuation increases the risk of MI, stroke and death; when possible interrupt 5 days before surgery with major bleeding risk and restart as soon as haemostasis is achieved.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• Dyspnoea occurs frequently (about 14-21% in trials), usually mild to moderate and often resolves.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• May cause false-negative platelet functional tests for heparin-induced thrombocytopenia.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A inhibitors (e.g. ketoconazole, clarithromycin, ritonavir)Substantially increase ticagrelor exposure; avoid.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A inducers (e.g. rifampin, phenytoin, carbamazepine)Reduce ticagrelor exposure and efficacy; avoid.DailyMed (U.S. National Library of Medicine)
• Opioids (e.g. morphine)Delay and reduce absorption; consider a parenteral antiplatelet in ACS patients needing opioids.DailyMed (U.S. National Library of Medicine)
• Simvastatin, lovastatin, rosuvastatinStatin levels increase; avoid simvastatin/lovastatin >40 mg/day; monitor with rosuvastatin.DailyMed (U.S. National Library of Medicine)
• DigoxinMonitor digoxin levels on initiation or change of ticagrelor.DailyMed (U.S. National Library of Medicine)

• Case-report data have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal/fetal outcomes; animal studies showed structural abnormalities at about 5-7 times the maximum human dose.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
• No human milk data; present in rat milk. Breastfeeding is not recommended during treatment.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• Monitor digoxin levels when co-administered; monitor for bleeding.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)

• يرتبط عكوسياً بمستقبل P2Y12 على الصفيحات فيثبط تنشيطها وتجمعها المعتمد على ADP.مضاد عكوس لمستقبلات P2Y12 للـ ADP (مضاد صفائح)